Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ligand Pharmaceuticals Inc. (NASDAQ: LGND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Ligand’s royalty‑focused biopharmaceutical business, financing activities and material agreements that support its model of funding mid‑ to late‑stage drug development, purchasing royalty rights and licensing technology platforms.
Ligand’s recent 8‑K filings describe events such as the completion of a private offering of 0.75% convertible senior notes due 2030, amendments to its credit agreement with Citibank, N.A., and the entry into material definitive agreements. Other 8‑Ks report quarterly financial results, including revenue composition and non‑GAAP measures, and discuss transactions like royalty financing agreements and the closing of a merger involving a Ligand subsidiary that became part of Pelthos Therapeutics. Filings also confirm that Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND and identify Jupiter, Florida as the location of its principal executive offices.
On Stock Titan, these SEC filings are paired with AI‑powered summaries designed to make complex regulatory language more accessible. Annual reports on Form 10‑K and quarterly reports on Form 10‑Q can be reviewed for discussions of Ligand’s business model, risk factors and segment information, while current reports on Form 8‑K highlight specific material events such as financings, credit facility amendments and significant portfolio transactions. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers.
Real‑time updates from EDGAR ensure that new LGND filings appear promptly, and AI analysis helps explain how each document relates to Ligand’s strategy of building diversified royalty and technology revenue streams. This combination allows investors and researchers to move efficiently from raw filings to a clearer understanding of the company’s regulatory and financial disclosures.
Ligand Pharmaceuticals (LGND) – Form 4 filing: Chief Financial Officer Octavio Espinoza acquired 224 common shares on 30 June 2025 through the company’s Employee Stock Purchase Plan (ESPP), a transaction coded “J,” which is exempt under Rules 16b-3(c) and 16b-3(d).
The shares were purchased at an average price of $91.08 per share, increasing Espinoza’s direct beneficial ownership to 29,852 shares. No derivative securities were reported in Table II. The filing was signed on 2 July 2025 by an attorney-in-fact on behalf of the executive.
Because the purchase occurred under an automatic ESPP rather than an open-market discretionary trade, the signal for insider sentiment is modest; however, it still marginally aligns executive and shareholder interests.
Form 3/A filing for Ligand Pharmaceuticals Inc. (LGND) discloses an amended initial beneficial ownership statement for Chief Financial Officer Octavio Espinoza.
- Date of event: 11/01/2022 (original Form 3 date); amendment filed 07/02/2025.
- Shares owned: 1,696 shares of LGND common stock reported as directly held.
- Purpose of amendment: Corrects the original Form 3, which inadvertently understated Mr. Espinoza’s direct holdings by exactly 1,696 shares. The correction also updates related Form 4 reports filed through the amendment date.
- Reporting person’s role: Officer – Chief Financial Officer.
No derivative securities are reported, and there are no other changes to ownership structure, relationships, or control disclosed in this filing.
Form 4 Filing Details: Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals (LGND), reported a sale of 500 shares of common stock on June 23, 2025, at an average price of $114.0843 per share.
Following the transaction, Reardon continues to hold 31,903 shares directly. The sale represents approximately 1.5% of his direct holdings. The transaction was reported within the required two-business-day filing deadline, with the Form 4 being filed on June 24, 2025.
This insider sale occurs at a time when LGND executives must comply with SEC regulations regarding insider trading. The filing indicates this was a direct ownership transaction, and no derivative securities were involved in this report.